S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
NASDAQ:BBIO

BridgeBio Pharma Stock Forecast, Price & News

$38.62
-1.41 (-3.52%)
(As of 12/3/2021 04:00 PM ET)
Add
Compare
Today's Range
$38.13
$40.03
50-Day Range
$38.04
$53.41
52-Week Range
$37.64
$73.50
Volume
1.09 million shs
Average Volume
814,212 shs
Market Capitalization
$5.68 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.84
30 days | 90 days | 365 days | Advanced Chart
Receive BBIO News and Ratings via Email

Sign-up to receive the latest news and ratings for BridgeBio Pharma and its competitors with MarketBeat's FREE daily newsletter.


BridgeBio Pharma logo

About BridgeBio Pharma

BridgeBio Pharma, Inc. engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases. Its pipeline of development programs includes product candidates ranging from early discovery to late-stage development. The company was founded by Charles Homcy, Frank McCormick, Philip Reilly, and Neil Kumar in 2015 and is headquartered in Palo Alto, CA.

Headlines

BridgeBio Pharma (NASDAQ:BBIO) Trading Up 4.2%
November 30, 2021 |  americanbankingnews.com
Reviewing BridgeBio Pharma (NASDAQ:BBIO) and Novan (NASDAQ:NOVN)
November 26, 2021 |  americanbankingnews.com
BridgeBio Pharma (NASDAQ:BBIO) Reaches New 52-Week Low at $39.26
November 26, 2021 |  americanbankingnews.com
BridgeBio Pharma Secures Debt Financing Of $750M
November 18, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BBIO
Fax
N/A
Employees
391
Year Founded
N/A

Sales & Book Value

Annual Sales
$8.25 million
Book Value
($5.02) per share

Profitability

Net Income
$-448.72 million
Net Margins
-939.99%
Pretax Margin
-999.43%

Debt

Price-To-Earnings

Miscellaneous

Free Float
104,207,000
Market Cap
$5.68 billion
Optionable
Not Optionable

Company Calendar

Last Earnings
11/04/2021
Today
12/05/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
2/24/2022

MarketRank

Overall MarketRank

2.25 out of 5 stars

Medical Sector

339th out of 1,388 stocks

Pharmaceutical Preparations Industry

148th out of 668 stocks

Analyst Opinion: 3.5Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.0 5 -4 -3 -2 -1 -












BridgeBio Pharma (NASDAQ:BBIO) Frequently Asked Questions

Is BridgeBio Pharma a buy right now?

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BridgeBio Pharma in the last twelve months. There are currently 9 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BridgeBio Pharma stock.
View analyst ratings for BridgeBio Pharma
or view top-rated stocks.

How has BridgeBio Pharma's stock been impacted by Coronavirus?

BridgeBio Pharma's stock was trading at $23.88 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, BBIO shares have increased by 61.7% and is now trading at $38.62.
View which stocks have been most impacted by COVID-19
.

When is BridgeBio Pharma's next earnings date?

BridgeBio Pharma is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
View our earnings forecast for BridgeBio Pharma
.

How were BridgeBio Pharma's earnings last quarter?

BridgeBio Pharma, Inc. (NASDAQ:BBIO) announced its quarterly earnings results on Thursday, November, 4th. The company reported ($1.06) EPS for the quarter, missing the consensus estimate of ($0.91) by $0.15. The firm had revenue of $2.34 million for the quarter, compared to the consensus estimate of $16.12 million. BridgeBio Pharma had a negative trailing twelve-month return on equity of 805.16% and a negative net margin of 939.99%. The firm's revenue was down 71.2% on a year-over-year basis.
View BridgeBio Pharma's earnings history
.

What price target have analysts set for BBIO?

9 brokers have issued 1-year price targets for BridgeBio Pharma's shares. Their forecasts range from $66.00 to $91.00. On average, they expect BridgeBio Pharma's share price to reach $80.50 in the next year. This suggests a possible upside of 108.4% from the stock's current price.
View analysts' price targets for BridgeBio Pharma
or view top-rated stocks among Wall Street analysts.

Who are BridgeBio Pharma's key executives?

BridgeBio Pharma's management team includes the following people:
  • Neil Kumar, Chief Executive Officer & Director
  • Christine E. Siu, Chief Operating Officer
  • Brian C. Stephenson, Chief Financial Officer & Secretary
  • Uma Sinha, Chief Scientific Officer
  • Richard H. Scheller, Director, Chairman-Research & Development (LinkedIn Profile)

What is 's approval rating as BridgeBio Pharma's CEO?

2 employees have rated BridgeBio Pharma CEO on Glassdoor.com. has an approval rating of 50% among BridgeBio Pharma's employees. This puts in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of BridgeBio Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BridgeBio Pharma investors own include Advanced Micro Devices (AMD), Gilead Sciences (GILD), Cisco Systems (CSCO), Johnson & Johnson (JNJ), Pfizer (PFE), Roku (ROKU), Editas Medicine (EDIT), Square (SQ), Sorrento Therapeutics (SRNE) and Sarepta Therapeutics (SRPT).

When did BridgeBio Pharma IPO?

(BBIO) raised $225 million in an initial public offering (IPO) on Thursday, June 27th 2019. The company issued 15,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs, Jefferies, SVB Leerink and KKR acted as the underwriters for the IPO and Piper Jaffray, Mizuho Securities, BMO Capital Markets and Raymond James were co-managers.

What is BridgeBio Pharma's stock symbol?

BridgeBio Pharma trades on the NASDAQ under the ticker symbol "BBIO."

Who are BridgeBio Pharma's major shareholders?

BridgeBio Pharma's stock is owned by a variety of institutional and retail investors. Top institutional investors include American International Group Inc. (2.53%), Janus Henderson Group PLC (1.80%), Geode Capital Management LLC (1.32%), Affinity Asset Advisors LLC (0.44%), Goldman Sachs Group Inc. (0.41%) and Fisher Asset Management LLC (0.38%). Company insiders that own BridgeBio Pharma stock include Brian C Stephenson, Cameron Turtle, Charles J Homcy, Frank Mccormick, Genetic Disorder LP Kkr, Michael Thomas Henderson, Neil Kumar, Randal W Scott and Richard H Scheller.
View institutional ownership trends for BridgeBio Pharma
.

Which major investors are selling BridgeBio Pharma stock?

BBIO stock was sold by a variety of institutional investors in the last quarter, including Citigroup Inc., BNP Paribas Arbitrage SA, Deutsche Bank AG, Bamco Inc. NY, Janus Henderson Group PLC, New York State Common Retirement Fund, Eagle Asset Management Inc., and Two Sigma Advisers LP. Company insiders that have sold BridgeBio Pharma company stock in the last year include Cameron Turtle, Genetic Disorder LP Kkr, and Richard H Scheller.
View insider buying and selling activity for BridgeBio Pharma
or view top insider-selling stocks.

Which major investors are buying BridgeBio Pharma stock?

BBIO stock was acquired by a variety of institutional investors in the last quarter, including Fisher Asset Management LLC, Alberta Investment Management Corp, Goldman Sachs Group Inc., Sectoral Asset Management Inc, Geode Capital Management LLC, Affinity Asset Advisors LLC, Millennium Management LLC, and UBS Group AG. Company insiders that have bought BridgeBio Pharma stock in the last two years include Brian C Stephenson, and Randal W Scott.
View insider buying and selling activity for BridgeBio Pharma
or or view top insider-buying stocks.

How do I buy shares of BridgeBio Pharma?

Shares of BBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BridgeBio Pharma's stock price today?

One share of BBIO stock can currently be purchased for approximately $38.62.

How much money does BridgeBio Pharma make?

BridgeBio Pharma has a market capitalization of $5.68 billion and generates $8.25 million in revenue each year. The company earns $-448.72 million in net income (profit) each year or ($3.91) on an earnings per share basis.

How many employees does BridgeBio Pharma have?

BridgeBio Pharma employs 391 workers across the globe.

What is BridgeBio Pharma's official website?

The official website for BridgeBio Pharma is bridgebio.com.

Where are BridgeBio Pharma's headquarters?

BridgeBio Pharma is headquartered at 421 Kipling Street, Palo Alto CA, 94301.

How can I contact BridgeBio Pharma?

BridgeBio Pharma's mailing address is 421 Kipling Street, Palo Alto CA, 94301. The company can be reached via phone at (650) 391-9740.


This page was last updated on 12/5/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.